Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bcg + neisvac-c + pediacel + infanrix + prevenar-13 + menitorix + priorix + rotarix
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intramuscular, Oral
01
Overview
This entry refers to a specific combination vaccine regimen evaluated in a University of Oxford pilot study (NCT01535638) titled 'Impact of BCG on MenC Vaccine Immunogenicity.' The regimen investigates the non-specific immunomodulatory effects of the Bacillus Calmette–Guérin (BCG) vaccine on the immune response to other routine childhood vaccines when administered at birth or at three months of age. The components of this regimen follow the United Kingdom childhood immunization schedule and include: **BCG** (live attenuated *Mycobacterium bovis*); **NeisVac-C** (a serogroup C meningococcal conjugate vaccine); **Pediacel** (a 5-in-1 DTaP-IPV-Hib vaccine); **Infanrix** (a DTaP vaccine); **Prevenar-13** (a 13-valent pneumococcal conjugate vaccine); **Menitorix** (a Hib-MenC conjugate vaccine); **Priorix** (a Measles-Mumps-Rubella vaccine); and **Rotarix** (a live attenuated oral rotavirus vaccine). The study's primary focus is to determine if the early administration of BCG enhances the immunogenicity of the meningococcal C (MenC) vaccine and other co-administered antigens through heterologous immune stimulation.
- Other names
- BCGBacillus Calmette-Guérin vaccineBCG, NeisVac-C, Pediacel, Infanrix, Prevenar-13, Menitorix, Priorix, Rotarix
02
Targets
B-cell receptor specific for rotavirus VP7 and VP4VP4 (Rotavirus VP4)VP7 (Rotavirus VP7 outer capsid glycoprotein)
Beyond the preview
Go deeper on bcg + neisvac-c + pediacel + infanrix + prevenar-13 + menitorix + priorix + rotarix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bcg + neisvac-c + pediacel + infanrix + prevenar-13 + menitorix + priorix + rotarix.